These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26864599)

  • 1. Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β.
    Di Fede G; Catania M; Maderna E; Morbin M; Moda F; Colombo L; Rossi A; Cagnotto A; Virgilio T; Palamara L; Ruggerone M; Giaccone G; Campagnani I; Costanza M; Pedotti R; Salvalaglio M; Salmona M; Tagliavini F
    Sci Rep; 2016 Feb; 6():20949. PubMed ID: 26864599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new β amyloid-derived peptide Aβ1-6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity.
    Diomede L; Romeo M; Cagnotto A; Rossi A; Beeg M; Stravalaci M; Tagliavini F; Di Fede G; Gobbi M; Salmona M
    Neurobiol Dis; 2016 Apr; 88():75-84. PubMed ID: 26792398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aβ1-6
    Diomede L; Zanier ER; Moro F; Vegliante G; Colombo L; Russo L; Cagnotto A; Natale C; Xodo FM; De Luigi A; Mosconi M; Beeg M; Catania M; Rossi G; Tagliavini F; Di Fede G; Salmona M
    Mol Psychiatry; 2023 Jun; 28(6):2433-2444. PubMed ID: 37198260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cell-permeable Aβ1-6A2VTAT(D) peptide reverts synaptopathy induced by Aβ1-42wt.
    Cimini S; Sclip A; Mancini S; Colombo L; Messa M; Cagnotto A; Di Fede G; Tagliavini F; Salmona M; Borsello T
    Neurobiol Dis; 2016 May; 89():101-11. PubMed ID: 26721320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide.
    Jiang N; Frenzel D; Schartmann E; van Groen T; Kadish I; Shah NJ; Langen KJ; Willbold D; Willuweit A
    Biochim Biophys Acta; 2016 Nov; 1858(11):2717-2724. PubMed ID: 27423267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's protective A2T mutation changes the conformational landscape of the Aβ₁₋₄₂ monomer differently than does the A2V mutation.
    Das P; Murray B; Belfort G
    Biophys J; 2015 Feb; 108(3):738-47. PubMed ID: 25650940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid β-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation.
    Zheng X; Liu D; Roychaudhuri R; Teplow DB; Bowers MT
    ACS Chem Neurosci; 2015 Oct; 6(10):1732-40. PubMed ID: 26244608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
    Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
    Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing.
    Hwang SH; Shin EJ; Shin TJ; Lee BH; Choi SH; Kang J; Kim HJ; Kwon SH; Jang CG; Lee JH; Kim HC; Nah SY
    J Alzheimers Dis; 2012; 31(1):207-23. PubMed ID: 22543851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer's disease.
    Catania M; Colombo L; Sorrentino S; Cagnotto A; Lucchetti J; Barbagallo MC; Vannetiello I; Vecchi ER; Favagrossa M; Costanza M; Giaccone G; Salmona M; Tagliavini F; Di Fede G
    Mol Psychiatry; 2022 Dec; 27(12):5227-5234. PubMed ID: 36028569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer's disease.
    Han M; Liu Y; Tan Q; Zhang B; Wang W; Liu J; Zhang XJ; Wang YY; Zhang JM
    Eur J Pharmacol; 2011 Apr; 657(1-3):104-10. PubMed ID: 21316359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A2T and A2V Aβ peptides exhibit different aggregation kinetics, primary nucleation, morphology, structure, and LTP inhibition.
    Murray B; Sorci M; Rosenthal J; Lippens J; Isaacson D; Das P; Fabris D; Li S; Belfort G
    Proteins; 2016 Apr; 84(4):488-500. PubMed ID: 26799157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.
    Kim HD; Tahara K; Maxwell JA; Lalonde R; Fukuiwa T; Fujihashi K; Van Kampen KR; Kong FK; Tang DC; Fukuchi K
    J Gene Med; 2007 Feb; 9(2):88-98. PubMed ID: 17219449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.
    Nieznanska H; Bandyszewska M; Surewicz K; Zajkowski T; Surewicz WK; Nieznanski K
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2143-2153. PubMed ID: 29604335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomegranate extract modulates processing of amyloid-β precursor protein in an aged Alzheimer's disease animal model.
    Ahmed AH; Subaiea GM; Eid A; Li L; Seeram NP; Zawia NH
    Curr Alzheimer Res; 2014; 11(9):834-43. PubMed ID: 25274111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
    Kim HD; Jin JJ; Maxwell JA; Fukuchi K
    Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthocyanin suppresses the toxicity of Aβ deposits through diversion of molecular forms in in vitro and in vivo models of Alzheimer's disease.
    Yamakawa MY; Uchino K; Watanabe Y; Adachi T; Nakanishi M; Ichino H; Hongo K; Mizobata T; Kobayashi S; Nakashima K; Kawata Y
    Nutr Neurosci; 2016; 19(1):32-42. PubMed ID: 26304685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.